The company has integrated its Eversense 365 implant with Sequel Med Tech’s insulin delivery system to automate the management of Type 1 diabetes.

Senseonics rolls out Eversense 365 integrated with Sequel's twiist AID system, aiming to boost CGM adoption with its ...

Sequel Med Tech and (NYSE:SENS) today announced the full U.S. launch of their CGM and insulin pump integration.

In combining the precision of the twiist insulin delivery system with the unmatched longevity of Eversense 365, Sequel and Senseonics are enhancing diabetes management by offering more tools to manage ...

Portal Diabetes has received the US FDA breakthrough device designation for its implantable insulin pump system, known as the Portal Pump.

Two steps toward bringing a functional cure to T1DWESTFIELD, Ind., Feb. 17, 2026 /PRNewswire/ -- Today, Portal Diabetes, Inc.

Portal Diabetes has received Breakthrough Device Designation by the Food and Drug Administration (FDA) for its implantable ...

Portal Diabetes announced today that it received FDA breakthrough device designation for its implantable insulin pump system.

Credence Research Inc. has released a new study on the Blood Glucose Monitoring Devices Market. According the report the Blood Glucose Monitoring Devices ...

The medical devices market is expected to register a compound annual growth rate (CAGR) of approximately 7% between 2026 and ...

The global patient monitoring device market size was US$ 21.1 billion in 2020. The global patient monitoring device market is forecast to grow to US$ 41.5 billion by 2030, registering a compound ...